Since completing BioInnovate in 2015, Garrett teamed up with Bioinnovate fellow Colm McGarvey to cofound Selio Medical, a company dedicated to developing a novel medical device to prevent pneumothorax during transthoracic needle biopsy. Following seed funding from Enterprise Ireland, in 2017 Selio Medical was subsequently accepted to the prestigious National Science Foundation I-corps Accelerator Program in Georgia Tech, Atlanta. The company was also selected to take part in the industry leading Medtech Innovator Accelerator in 2017 in San Francisco where they placed third out of 600 entries. Garrett (CTO) and Colm (CEO) wish to 'spin-out' Selio Medical from Trinity College Dublin in late-2018 and are currently seeking a Series A investment of €2.5million to bring the technology to First in Human clinical trials in 2019.